The 340B Drug Pricing Program, while aimed at supporting healthcare, inadvertently raises property taxes for local communities by incentivizing nonprofit hospital acquisitions of for-profit entities.
About:
Dan Snow is a researcher and data scientist focused on U.S. healthcare pricing and data transparency, with experience in public policy and property tax data science.
Website:
Specializations:
Interests:
Outgoing Links:
Subscribe to RSS:
Rural hospitals receive significantly lower reimbursement rates from commercial insurers compared to urban hospitals, risking their financial viability and community health outcomes.
The 340B Drug Pricing Program has shifted from aiding low-income patients to becoming a profit source for large hospitals in Illinois, raising transparency and effectiveness concerns.
The OBBB Act threatens the financial stability of over 300 hospitals by disqualifying them from the 340B Drug Pricing Program due to Medicaid spending cuts.
The post examines the compliance and impact of the CMS mandate on hospital price transparency, highlighting challenges in data utilization and the author's plans for future analyses.
Vendors are exploiting a loophole in the Blue Cross Blue Shield network, profiting from price discrepancies while increasing costs for patients through BlueCard underpayments.
Price Points analyzes U.S. childbirth costs, revealing significant price variations influenced by geography, care complexity, and insurer negotiations, while emphasizing the need for healthcare pricing transparency.
Hoag and Blue Shield's public contract dispute reflects a growing trend in U.S. healthcare, emphasizing the need for price transparency to empower patients.